STOCK TITAN

[8-K] Horizon Space Acquisition I Corp. Unit Reports Material Event

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Regencell Bioscience Holdings Limited (RGC) filed a Form 6-K announcing a board change effective 30 June 2025.

  • Appointment: Ms. Margaret Hoor Han Lo joins the board as an independent director and will sit on the audit, compensation, and nominating & corporate governance committees.
  • Background: Ms. Lo brings 30+ years of real-estate investment experience and has no family ties to existing officers or directors.
  • Resignation: Independent director Mr. Paul J. Niewiadomski resigned for personal reasons on the same date; he previously chaired the nominating & corporate governance committee and served on the audit and compensation committees.
  • No disagreements: The company states the resignation was not due to any dispute over operations, policies, or practices. Mr. Niewiadomski will remain in an advisory capacity.

Other than the governance transition, the filing contains no financial or operational updates.

Regencell Bioscience Holdings Limited (RGC) ha presentato un Modulo 6-K annunciando una modifica nel consiglio di amministrazione con effetto dal 30 giugno 2025.

  • Nomina: La signora Margaret Hoor Han Lo entra a far parte del consiglio come direttrice indipendente e farà parte dei comitati di revisione, compensi e nomine & governance aziendale.
  • Profilo: La signora Lo vanta oltre 30 anni di esperienza negli investimenti immobiliari e non ha legami familiari con dirigenti o amministratori esistenti.
  • Dimissioni: Il direttore indipendente, signor Paul J. Niewiadomski, si è dimesso per motivi personali nella stessa data; in precedenza presiedeva il comitato nomine & governance aziendale e faceva parte dei comitati revisione e compensi.
  • Nessun disaccordo: L’azienda dichiara che le dimissioni non sono dovute a controversie su operazioni, politiche o pratiche. Il signor Niewiadomski resterà in veste di consulente.

Oltre alla transizione di governance, il documento non contiene aggiornamenti finanziari o operativi.

Regencell Bioscience Holdings Limited (RGC) presentó un Formulario 6-K anunciando un cambio en la junta directiva efectivo el 30 de junio de 2025.

  • Nombramiento: La Sra. Margaret Hoor Han Lo se incorpora a la junta como directora independiente y formará parte de los comités de auditoría, compensación y nominaciones & gobierno corporativo.
  • Antecedentes: La Sra. Lo aporta más de 30 años de experiencia en inversiones inmobiliarias y no tiene vínculos familiares con los actuales oficiales o directores.
  • Renuncia: El director independiente Sr. Paul J. Niewiadomski renunció por motivos personales en la misma fecha; anteriormente presidía el comité de nominaciones & gobierno corporativo y formaba parte de los comités de auditoría y compensación.
  • Sin desacuerdos: La empresa declara que la renuncia no se debió a disputas sobre operaciones, políticas o prácticas. El Sr. Niewiadomski permanecerá en calidad de asesor.

Aparte de la transición en la gobernanza, el informe no contiene actualizaciones financieras u operativas.

Regencell Bioscience Holdings Limited (RGC)는 2025년 6월 30일부로 이사회 변경 사항을 발표하는 Form 6-K를 제출했습니다.

  • 임명: Margaret Hoor Han Lo 씨가 독립 이사로 이사회에 합류하며 감사, 보상, 지명 및 기업 지배구조 위원회에 참여합니다.
  • 배경: Lo 씨는 30년 이상의 부동산 투자 경험을 보유하고 있으며 기존 임원이나 이사와 가족 관계가 없습니다.
  • 사임: 독립 이사인 Paul J. Niewiadomski 씨는 같은 날짜에 개인 사유로 사임했으며, 이전에는 지명 및 기업 지배구조 위원회를 이끌고 감사 및 보상 위원회에 참여했습니다.
  • 이견 없음: 회사는 사임이 운영, 정책 또는 관행과 관련된 분쟁 때문이 아니라고 밝혔으며, Niewiadomski 씨는 자문 역할을 계속 수행할 예정입니다.

거버넌스 전환 외에는 재무나 운영 관련 업데이트가 포함되어 있지 않습니다.

Regencell Bioscience Holdings Limited (RGC) a déposé un formulaire 6-K annonçant un changement au sein du conseil d'administration effectif au 30 juin 2025.

  • Nomination : Mme Margaret Hoor Han Lo rejoint le conseil en tant qu'administratrice indépendante et siégera aux comités d'audit, de rémunération, ainsi que de nomination et gouvernance d'entreprise.
  • Parcours : Mme Lo apporte plus de 30 ans d'expérience dans l'investissement immobilier et n'a aucun lien familial avec les dirigeants ou administrateurs actuels.
  • Démission : L'administrateur indépendant M. Paul J. Niewiadomski a démissionné pour raisons personnelles à la même date ; il présidait auparavant le comité de nomination et gouvernance d'entreprise et siégeait aux comités d'audit et de rémunération.
  • Pas de désaccord : La société précise que la démission ne résulte d'aucun différend concernant les opérations, politiques ou pratiques. M. Niewiadomski restera en qualité de conseiller.

En dehors de cette transition de gouvernance, le dépôt ne contient aucune mise à jour financière ou opérationnelle.

Regencell Bioscience Holdings Limited (RGC) hat ein Formular 6-K eingereicht, das eine Änderung im Vorstand mit Wirkung zum 30. Juni 2025 ankündigt.

  • Ernennung: Frau Margaret Hoor Han Lo tritt als unabhängiges Vorstandsmitglied bei und wird in den Ausschüssen für Prüfung, Vergütung sowie Nominierung & Unternehmensführung tätig sein.
  • Hintergrund: Frau Lo bringt über 30 Jahre Erfahrung im Bereich Immobilieninvestitionen mit und hat keine familiären Verbindungen zu aktuellen Führungskräften oder Vorstandsmitgliedern.
  • Rücktritt: Der unabhängige Vorstand Herr Paul J. Niewiadomski ist aus persönlichen Gründen zum selben Datum zurückgetreten; er leitete zuvor den Ausschuss für Nominierung & Unternehmensführung und war Mitglied der Prüfungs- und Vergütungsausschüsse.
  • Keine Meinungsverschiedenheiten: Das Unternehmen erklärt, dass der Rücktritt nicht auf Streitigkeiten über Abläufe, Richtlinien oder Praktiken zurückzuführen ist. Herr Niewiadomski wird weiterhin beratend tätig sein.

Abgesehen von der Governance-Umstellung enthält die Einreichung keine finanziellen oder operativen Aktualisierungen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Board vacancy filled same day; committees remain staffed—impact limited.

The simultaneous resignation and appointment keep Regencell in compliance with Nasdaq and Cayman governance requirements, avoiding prolonged committee vacancies. Ms. Lo’s extensive investment background offers fresh oversight perspectives, notably on the audit committee. Retaining Mr. Niewiadomski as an advisor mitigates institutional knowledge loss. Because no operational disagreements are cited, the change appears orderly and should not alter strategic direction. Investors should monitor future committee leadership designations once roles are formally reassigned.

TL;DR: Routine board shuffle—no immediate valuation driver.

From a portfolio standpoint, the filing is governance-specific with negligible earnings or cash-flow implications. Ms. Lo’s real-estate focus does not obviously enhance biotech R&D insight, yet her capital allocation experience could aid risk oversight. Continuity risk is low since Mr. Niewiadomski departs amicably and stays on as advisor. Overall, the disclosure is neutral; I would not adjust position sizing based solely on this event.

Regencell Bioscience Holdings Limited (RGC) ha presentato un Modulo 6-K annunciando una modifica nel consiglio di amministrazione con effetto dal 30 giugno 2025.

  • Nomina: La signora Margaret Hoor Han Lo entra a far parte del consiglio come direttrice indipendente e farà parte dei comitati di revisione, compensi e nomine & governance aziendale.
  • Profilo: La signora Lo vanta oltre 30 anni di esperienza negli investimenti immobiliari e non ha legami familiari con dirigenti o amministratori esistenti.
  • Dimissioni: Il direttore indipendente, signor Paul J. Niewiadomski, si è dimesso per motivi personali nella stessa data; in precedenza presiedeva il comitato nomine & governance aziendale e faceva parte dei comitati revisione e compensi.
  • Nessun disaccordo: L’azienda dichiara che le dimissioni non sono dovute a controversie su operazioni, politiche o pratiche. Il signor Niewiadomski resterà in veste di consulente.

Oltre alla transizione di governance, il documento non contiene aggiornamenti finanziari o operativi.

Regencell Bioscience Holdings Limited (RGC) presentó un Formulario 6-K anunciando un cambio en la junta directiva efectivo el 30 de junio de 2025.

  • Nombramiento: La Sra. Margaret Hoor Han Lo se incorpora a la junta como directora independiente y formará parte de los comités de auditoría, compensación y nominaciones & gobierno corporativo.
  • Antecedentes: La Sra. Lo aporta más de 30 años de experiencia en inversiones inmobiliarias y no tiene vínculos familiares con los actuales oficiales o directores.
  • Renuncia: El director independiente Sr. Paul J. Niewiadomski renunció por motivos personales en la misma fecha; anteriormente presidía el comité de nominaciones & gobierno corporativo y formaba parte de los comités de auditoría y compensación.
  • Sin desacuerdos: La empresa declara que la renuncia no se debió a disputas sobre operaciones, políticas o prácticas. El Sr. Niewiadomski permanecerá en calidad de asesor.

Aparte de la transición en la gobernanza, el informe no contiene actualizaciones financieras u operativas.

Regencell Bioscience Holdings Limited (RGC)는 2025년 6월 30일부로 이사회 변경 사항을 발표하는 Form 6-K를 제출했습니다.

  • 임명: Margaret Hoor Han Lo 씨가 독립 이사로 이사회에 합류하며 감사, 보상, 지명 및 기업 지배구조 위원회에 참여합니다.
  • 배경: Lo 씨는 30년 이상의 부동산 투자 경험을 보유하고 있으며 기존 임원이나 이사와 가족 관계가 없습니다.
  • 사임: 독립 이사인 Paul J. Niewiadomski 씨는 같은 날짜에 개인 사유로 사임했으며, 이전에는 지명 및 기업 지배구조 위원회를 이끌고 감사 및 보상 위원회에 참여했습니다.
  • 이견 없음: 회사는 사임이 운영, 정책 또는 관행과 관련된 분쟁 때문이 아니라고 밝혔으며, Niewiadomski 씨는 자문 역할을 계속 수행할 예정입니다.

거버넌스 전환 외에는 재무나 운영 관련 업데이트가 포함되어 있지 않습니다.

Regencell Bioscience Holdings Limited (RGC) a déposé un formulaire 6-K annonçant un changement au sein du conseil d'administration effectif au 30 juin 2025.

  • Nomination : Mme Margaret Hoor Han Lo rejoint le conseil en tant qu'administratrice indépendante et siégera aux comités d'audit, de rémunération, ainsi que de nomination et gouvernance d'entreprise.
  • Parcours : Mme Lo apporte plus de 30 ans d'expérience dans l'investissement immobilier et n'a aucun lien familial avec les dirigeants ou administrateurs actuels.
  • Démission : L'administrateur indépendant M. Paul J. Niewiadomski a démissionné pour raisons personnelles à la même date ; il présidait auparavant le comité de nomination et gouvernance d'entreprise et siégeait aux comités d'audit et de rémunération.
  • Pas de désaccord : La société précise que la démission ne résulte d'aucun différend concernant les opérations, politiques ou pratiques. M. Niewiadomski restera en qualité de conseiller.

En dehors de cette transition de gouvernance, le dépôt ne contient aucune mise à jour financière ou opérationnelle.

Regencell Bioscience Holdings Limited (RGC) hat ein Formular 6-K eingereicht, das eine Änderung im Vorstand mit Wirkung zum 30. Juni 2025 ankündigt.

  • Ernennung: Frau Margaret Hoor Han Lo tritt als unabhängiges Vorstandsmitglied bei und wird in den Ausschüssen für Prüfung, Vergütung sowie Nominierung & Unternehmensführung tätig sein.
  • Hintergrund: Frau Lo bringt über 30 Jahre Erfahrung im Bereich Immobilieninvestitionen mit und hat keine familiären Verbindungen zu aktuellen Führungskräften oder Vorstandsmitgliedern.
  • Rücktritt: Der unabhängige Vorstand Herr Paul J. Niewiadomski ist aus persönlichen Gründen zum selben Datum zurückgetreten; er leitete zuvor den Ausschuss für Nominierung & Unternehmensführung und war Mitglied der Prüfungs- und Vergütungsausschüsse.
  • Keine Meinungsverschiedenheiten: Das Unternehmen erklärt, dass der Rücktritt nicht auf Streitigkeiten über Abläufe, Richtlinien oder Praktiken zurückzuführen ist. Herr Niewiadomski wird weiterhin beratend tätig sein.

Abgesehen von der Governance-Umstellung enthält die Einreichung keine finanziellen oder operativen Aktualisierungen.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 27, 2025

 

HORIZON SPACE ACQUISITION I CORP.

(Exact name of registrant as specified in its charter)

 

Cayman Islands

 

001-41578

 

N/A

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number) 

 

Identification Number)

 

1412 Broadway, 21st Floor, Suite 21V

New York, NY 10018

(Address of principal executive offices)

 

(646) 257-5537

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act.

 

Title of each class

 

Trading

Symbol

 

Name of each exchange

on which registered

Units, consisting of one Ordinary Share, $0.0001 par value, one redeemable Warrant to acquire one Ordinary Share, and one Right to acquire one-tenth of one Ordinary Share

 

HSPOU

 

The Nasdaq Stock Market LLC

Ordinary Shares, par value $0.0001 per share

 

HSPO

 

The Nasdaq Stock Market LLC

Redeemable Warrants, each whole warrant exercisable for one Ordinary Share at an exercise price of $11.50

 

HSPOW

 

The Nasdaq Stock Market LLC

Rights, each whole right to acquire one-tenth of one Ordinary Share

 

HSPOR

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

The disclosures set forth under Item 2.03 are incorporated by reference.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

Horizon Space Acquisition I Corp., a Cayman Islands exempted company (the “Company” or “HSPO”), had until June 27, 2025 to complete its initial business combination pursuant to its amended and restated memorandum and articles of association. However, the Company may extend the period of time to consummate a business combination by up to six one-month extensions, up to December 27, 2025, subject to Horizon Space Acquisition I Sponsor Corp., a Cayman Islands company, the sponsor of the Company (the “Sponsor”) and/or its designee, depositing $120,000 (the “Monthly Extension Fee”) into the trust account of the Company (the “Trust Account”).

 

On June 26, 2025, an aggregate of $120,000 of the Monthly Extension Fee was deposited into the Trust Account for the public shareholders, which enables the Company to extend the period of time it has to consummate its initial business combination by one month from June 27, 2025 to July 27, 2025 (the “Extension”). The payment of the Monthly Extension Fee was made by Shenzhen Squirrel Enlivened Media Group Co., Ltd. ( “Squirrel Shenzhen”), pursuant to that certain Agreement and Plan of Merger (the “Business Combination Agreement”) dated September 16, 2024, by and among the Company, Squirrel Enlivened Technology Co., Ltd, a Cayman Islands exempted company (“Squirrel HoldCo”), Squirrel Enlivened International Co., Ltd, a Cayman Islands exempted company and a wholly-owned subsidiary of Squirrel HoldCo (“Squirrel Cayman”), Squirrel Enlivened Overseas Co., Ltd, a Cayman Islands exempted company and a wholly-owned subsidiary of Squirrel Cayman (“Merger Sub”) in connection with the proposed business combination (the “Business Combination”). The Company issued an unsecured promissory note in the aggregate principal amount of $120,000 (the “Note”) dated May 28, 2025 to Squirrel Shenzhen in connection with the payment of the Monthly Extension Fee.

 

The Note bears no interest and is payable in full upon the earlier to occur of (i) the consummation of the Company’s business combination or (ii) the date of expiry of the term of the Company (the “Maturity Date”). The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date; (ii) the commencement of a voluntary or involuntary bankruptcy action, (iii) the breach of the Company’s obligations thereunder; (iv) any cross defaults; (v) an enforcement proceedings against the Company; and (vi) any unlawfulness and invalidity in connection with the performance of the obligations thereunder, in which case the Note may be accelerated.

 

A copy of the Note is attached as Exhibit 10.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference. The foregoing description of the Note does not purport to be complete and is subject to, and is qualified in its entirety by, the full text of the Note.

 

 
2

 

 

Forward-Looking Statements

 

This Report includes forward looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “target,” “aim,” “plan,” “project,” “forecast,” “should,” “would,” or variations of such words or by expressions of similar meaning. Such forward-looking statements, including statements regarding anticipated financial and operational results, projections of market opportunity and expectations, the estimated post-transaction enterprise value, the advantages and expected growth of Squirrel HoldCo and its subsidiaries, including among others Squirrel Cayman, Merger Sub and Shenzhen Squirrel (collectively as enumerated in accordance with the Business Combination Agreement, the “Squirrel Companies”) , the cash position of Squirrel Companies following the Merger Closing (as defined in the Business Combination Agreement), the ability of Squirrel Companies and HSPO to consummate the proposed Business Combination and the timing of such consummation, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section entitled “Risk Factors” in HSPO’s Annual Report on Form 10-K filed with the SEC on March 28, 2025 (the “Form 10-K”), HSPO’s final prospectus dated December 22, 2022 filed with the SEC (the “Final Prospectus”) related to HSPO’s initial public offering, and in other documents filed by HSPO with the SEC from time to time. Important factors that could cause the combined company’s actual results or outcomes to differ materially from those discussed in the forward-looking statements include: HSPO’s or Squirrel Companies’ limited operating history; the ability of HSPO or Parent to identify and integrate acquisitions; general economic and market conditions impacting demand for the services of Squirrel Companies; the inability to complete the proposed Business Combination; the inability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, the amount of cash available following any redemptions by HSPO shareholders; the ability to meet Nasdaq’s listing standards following the consummation of the proposed Business Combination; costs related to the proposed Business Combination; and such other risks and uncertainties as are discussed in the Form 10-K, the Final Prospectus and the proxy statement to be filed relating to the Business Combination. Other factors include the possibility that the proposed Business Combination do not close, including due to the failure to receive required security holder approvals, or the failure of other closing conditions.

 

Squirrel Companies and HSPO each expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the expectations of Squirrel Companies or HSPO with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

 

Additional Information about the Transaction and Where to Find It

 

In connection with the proposed Business Combination, Squirrel Cayman has filed with the SEC a registration statement on Form F-4, which  includes a preliminary proxy statement containing information about the proposed Business Combination and the respective businesses of Squirrel Companies and HSPO, as well as the prospectus relating to the offer of the Parent securities to be issued to in connection with the completion of the proposed Business Combination. After the registration statement is declared effective, HSPO will mail a definitive proxy statement and other relevant documents to its shareholders as of the record date established for voting on the proposed Business Combination.

 

INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ, WHEN AVAILABLE, THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION AND THE PARTIES TO THE BUSINESS COMBINATION. Investors and security holders will be able to obtain copies of these documents (if and when available) and other documents filed with the SEC free of charge at www.sec.gov. Shareholders of HSPO will also be able to obtain copies of the proxy statement/prospectus without charge, once available, at the SEC’s website at www.sec.gov.

 

Participants in the Solicitation

 

Squirrel HoldCo, Squirrel Cayman, HSPO and their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from HSPO’s shareholders with respect to the proposed Business Combination. Information regarding HSPO’s directors and executive officers is available in HSPO’s filings with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be deemed to be participants in the proxy solicitation relating to the proposed Business Combination and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus when it becomes available.

 

No Offer or Solicitation

 

This Report does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

 

 
3

 

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit No.

 

Description

10.1

 

Extension Promissory Note, dated June 27, 2025, issued by the Company to Shenzhen Squirrel Enlivened Media Group Co., Ltd.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
4

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Horizon Space Acquisition I Corp.

 

 

 

 

Date: June 30, 2025

By:

/s/ Mingyu (Michael) Li

 

 

Name: 

Mingyu (Michael) Li

 

 

Title:

Chief Executive Officer

 

 

 
5

 

Horizon Space Acquisition I Corp

NASDAQ:HSPOU

HSPOU Rankings

HSPOU Latest News

HSPOU Stock Data

6.35M
0.07%
Shell Companies
Blank Checks
United States
NEW YORK